Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Bryn Mawr Trust Advisors LLC

Bryn Mawr Trust Advisors LLC lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 74.6% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 10,125 shares of the medical equipment provider’s stock after selling 29,699 shares during the period. Bryn Mawr Trust Advisors LLC’s holdings in Zimmer Biomet were worth $915,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of ZBH. Main Management ETF Advisors LLC grew its holdings in Zimmer Biomet by 1.0% during the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock worth $986,000 after acquiring an additional 112 shares during the period. Citizens National Bank Trust Department boosted its holdings in Zimmer Biomet by 17.6% during the first quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider’s stock worth $85,000 after buying an additional 141 shares in the last quarter. Boltwood Capital Management grew its position in Zimmer Biomet by 3.9% during the fourth quarter. Boltwood Capital Management now owns 3,866 shares of the medical equipment provider’s stock valued at $348,000 after buying an additional 144 shares during the period. Independence Bank of Kentucky grew its position in Zimmer Biomet by 9.7% during the fourth quarter. Independence Bank of Kentucky now owns 1,633 shares of the medical equipment provider’s stock valued at $147,000 after buying an additional 145 shares during the period. Finally, LOM Asset Management Ltd increased its holdings in Zimmer Biomet by 21.5% in the fourth quarter. LOM Asset Management Ltd now owns 830 shares of the medical equipment provider’s stock valued at $75,000 after buying an additional 147 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insiders Place Their Bets

In related news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.28% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ZBH shares. Stifel Nicolaus decreased their price objective on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a research report on Wednesday, April 29th. Robert W. Baird set a $92.00 target price on Zimmer Biomet in a research report on Wednesday, April 29th. Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Monday, July 6th. Leerink Partners started coverage on Zimmer Biomet in a report on Monday, April 13th. They issued a “hold” rating and a $101.00 price target for the company. Finally, Truist Financial reiterated a “hold” rating and set a $92.00 price target (down from $98.00) on shares of Zimmer Biomet in a research report on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $100.70.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $90.90 on Wednesday. The firm has a market cap of $17.59 billion, a PE ratio of 23.61, a PEG ratio of 2.77 and a beta of 0.46. The firm has a fifty day moving average of $86.65 and a 200 day moving average of $89.80. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $108.29.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. During the same period last year, the firm posted $1.81 earnings per share. The company’s revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is 24.94%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.